Related Experiment Video
Updated: Aug 4, 2026
Selected Reaction Monitoring Mass Spectrometry for Absolute Protein Quantification
Published on: August 17, 2015
The search for the ideal SERM
Banu Arun1, Marietta Anthony, Barbara Dunn
1Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA. barun@mdanderson.org
Abstract:
Selective oestrogen receptor modulators (SERMs) are compounds that interact with the oestrogen receptor and have tissue-specific effects distinct from those of oestradiol, acting as an oestrogen agonist in some tissues and as an antagonist in others. The development of SERMs that selectively interact with specific receptors, coactivators and corepressors in different organ systems offers the possibility of improving the risk:benefit profile relative to hormone replacement therapy. Tamoxifen is a SERM that acts as an oestrogen antagonist in breast tissue and is currently being used for the treatment and prevention of breast cancer. Tamoxifen also exhibits oestrogen-agonistic properties in the endometrium and increases the risk of endometrial cancer. Oestrogen and another SERM, raloxifene, have been shown to prevent osteoporosis. The effects of oestrogens on cognitive functions are currently being investigated. Recent data reveal the lack of secondary prevention of coronary heart disease with oestrogen. Oestrogen has been used to treat menopausal symptoms, whereas the SERMs have been shown to induce hot flushes. Current research is focused on producing the ideal SERM, which would have benefits over existing SERMs in terms of preventing cancer, cardiovascular disease, osteoporosis and menopausal symptoms, improving cognitive functions, and have a significantly better toxicity profile in terms of endometrial cancer and thromboembolic events.
Insights
Selective oestrogen receptor modulators (SERMs) offer targeted effects, acting as agonists or antagonists in specific tissues. Research aims to develop ideal SERMs with improved benefits for cancer, bone health, and cognition, while minimizing risks like endometrial cancer.
Area of Science:
- Endocrinology and Pharmacology
- Molecular Biology
- Oncology
Background:
- Selective oestrogen receptor modulators (SERMs) interact with oestrogen receptors, exhibiting tissue-specific agonist or antagonist activity.
- SERMs offer potential for improved risk:benefit profiles compared to traditional hormone replacement therapy.
- Current SERMs like tamoxifen have demonstrated efficacy but also associated risks, such as endometrial cancer.
Purpose of the Study:
- To review the current landscape of SERM development and their therapeutic applications.
- To highlight the potential of novel SERMs in addressing unmet needs in women's health.
- To outline the ongoing research efforts towards developing an ideal SERM with enhanced efficacy and safety.
Main Methods:
- Literature review of existing studies on SERMs, oestrogen, and hormone replacement therapy.
- Analysis of clinical data regarding the efficacy and toxicity profiles of various SERMs.
- Exploration of emerging research on molecular mechanisms and therapeutic targets for SERMs.
Main Results:
- Tamoxifen acts as an oestrogen antagonist in breast tissue, aiding cancer treatment, but is an agonist in the endometrium, increasing cancer risk.
- Oestrogen and raloxifene show efficacy in preventing osteoporosis, while oestrogen has not demonstrated secondary prevention for coronary heart disease.
- SERMs can induce menopausal symptoms like hot flushes, contrasting with oestrogen's use in symptom management.
Conclusions:
- The development of ideal SERMs is crucial for simultaneously addressing multiple health concerns including cancer, cardiovascular disease, osteoporosis, and menopausal symptoms.
- Future SERMs aim to maximize therapeutic benefits while significantly improving safety profiles, particularly concerning endometrial cancer and thromboembolic events.
- Targeted modulation of oestrogen receptor pathways holds promise for personalized medicine in women's health.
